Citadel Advisors
IBIO icon

Citadel Advisors’s iBio IBIO Stock Holding History

Citadel Advisors’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10
Closed -$14 – 14962
2023
Q4 		$14 Buy
10
+5
+100% +$22 ﹤0.01% 14159
2023
Q3 		$30 Sell
5
-5
-50% -$43 ﹤0.01% 14191
2023
Q2 		$122 Buy
+10
New +$189 ﹤0.01% 14215
2022
Q3 		– Sell
-48
Closed -$6K – 13049
2022
Q2 		$6K Sell
48
-49
-51% -$7.37K ﹤0.01% 12663
2022
Q1 		$21K Sell
97
-10
-9% -$2.09K ﹤0.01% 13222
2021
Q4 		$29K Sell
107
-113
-51% -$43.1K ﹤0.01% 13486
2021
Q3 		$117K Sell
220
-252
-53% -$157K ﹤0.01% 12678
2021
Q2 		$356K Buy
472
+234
+98% +$171K ﹤0.01% 10855
2021
Q1 		$183K Buy
238
+29
+14% +$25.3K ﹤0.01% 11807
2020
Q4 		$110K Buy
209
+144
+222% +$117K ﹤0.01% 10168
2020
Q3 		$66K Buy
+65
New +$94.2K ﹤0.01% 9491

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors's IBIO Position: Q2 2026 in Review

Citadel Advisors increased its iBio (IBIO) stake by 45% in Q2 2026, buying an estimated $765K and bringing the position to 1,384,029 shares worth $2.42M. The position accounts for ﹤0.01% of the portfolio, ranked #6134.

Citadel Advisors first reported a position in IBIO in Q3 2013 and has held it in 29 quarters since. 55 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Citadel Advisors held 1,384,029 shares of iBio worth $2.42M as of Q2 2026.
  • Citadel Advisors bought 427,600 iBio shares in Q2 2026, an estimated $765K.
  • iBio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6134 holding.
  • Citadel Advisors first reported a position in iBio in Q3 2013 and has held it in 29 quarters since.
  • 55 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.